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Abstract
The central nervous system (CNS) is a central pillar in safety pharmacology studies of 
new drugs. Characterization of serious adverse drug reactions to a new chemical entity 
involves extensive investigation using in vitro and in vivo models. However, primary cul-
ture of human neurons in vitro can be challenging, giving limited sample availability. 
Additionally, the inter-species differences between humans and current animal models 
impose a considerable obstacle to successfully predict the outcome of new drugs. New 
technologies also need to help address the 3Rs principles in animal research. Human 
pluripotent stem cells (hPSC) have the potential to change the current paradigm in 
pharmacological research. By using hPSCs and state-of-the-art differentiation protocols, 
researchers now have available an unlimited source of neural cells, able to mimic early 
and late stage of human CNS development. Moreover, hPSC-derived cells can be used at 
early stages of drug development, improving clinical predictability and reducing overall 
drug development costs. This chapter covers the advancements that resulted in hPSC-
derived models intended to enable neurotoxicity assessment and drug screening. Finally, 
this chapter will also reveal the bottlenecks and the challenges to overcome of using hPSC 
as a predictive tool in research.
Keywords: human pluripotent stem cells (hPSC), induced pluripotent stem cells (iPSC), 
multielectrode array (MEA), Zika virus, neurotoxicity
1. Introduction
1.1. New therapeutic compounds and the nervous system
The human central nervous system (CNS) is a unique structure organized in an intricate net-
work composed of different cell types [1, 2]. Its homeostasis is maintained by an orchestrated 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
signaling milieu composed of neurotransmitters, cell-cell interactions, and protein factors. 
Any compound acting upon one of the CNS components could potentially shift this delicate 
balance, resulting in untoward outcomes. Therefore, safety pharmacology profiling for com-
pounds that crosses the blood-brain barrier represents a key step in the drug development 
process, particular prior to conducting studies in human subjects. Recently, the Biotechnology 
Innovation Organization (BIO) released the largest study of clinical drug development success 
rates to date [3]. In partnership with Amplion and Biomedtracker, BIO collected and analyzed 
a total of 9985 phase transitions in clinical trials between 2006 and 2015. Their data revealed 
a likelihood of approval being of only 9.6% for all developmental candidates. If segmented 
by diseases, candidates to neurology and psychiatry disorders fall under 9.6%, with 8.4 and 
6.2% likelihood of approval, respectively. Moreover, adverse effects to the CNS account for a 
considerable proportion of all drug attrition cases. This demonstrates the poor predictability 
of current animal and in vitro models leveraged at the pre-clinical drug development stage.
Assessing the toxicological profile of new molecular entities requires extensive investigation 
using in vitro and in vivo models (Figure 1). This incremental accumulation of data helps to 
evaluate the toxicological profile and potential side effects of new compounds before moving to 
clinical trials. Studies to investigate the toxicity of drugs on the human central nervous system 
(CNS) relies mostly on animal (in vivo) and cellular (in vitro) models [4]. Although significant 
achievements have been accomplished using these models, there are many bottlenecks to over-
come. For instance, efforts to fully recapitulate the human nervous system using animal models 
can be very challenging [5]. Rodents and human brains display major genetic, cellular, and ana-
tomical differences [6]. Many compounds have failed in clinical trials even after being consid-
ered promising based on rigorous testing in animal models. Therapies to Alzheimer’s disease 
(AD) for example have an attrition rate of 99.6% [7]. Many potential  therapeutic compounds 
Figure 1. In vitro and in vivo models available for toxicological screenings. As the complexity of the model increases, 
there is a substantial decrease in throughput. Common cellular models include immortalized cell lines, primary tissue 
culture and hPSC-derived cells. Organoids are 3D structures derived from hPSC differentiation toward neuroectoderm 
in suspension.
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for AD displayed unacceptable toxicity in humans. Additionally, while animal models have 
unquestionable importance in toxicological studies, new technologies could uniquely help to 
address the 3R principles of refine, reduce, and replace their use in this research space [8].
There are two main in vitro cellular models available for toxicology studies: primary and 
established cell lines [9, 10]. Primary cell lines are isolated directly from tissues. Their main 
advantage is that they more closely remember the in vivo counterpart, displaying many fea-
tures presented in the target tissue. However, primary cell lines need fresh tissue to estab-
lish the cell culture and have limited capability of expansion in vitro. This turns impractical 
Studies that require large numbers of cells, especially from difficult-to-obtain tissue such as 
the human central nervous system. Immortalized cell lines, on the other hand, can be kept 
in culture for extensive periods of time and expanded through passaging. The immortalized 
cells have the intrinsic ability to proliferate indefinitely in culture, usually acquired by mul-
tiple mutations or transformations in their genomes. Although the proliferative potentials 
for immortalized cells make them amenable to large-scale production, they may significantly 
differ from the tissue of origin. Given the limitations imposed by these types of cell culture, 
human pluripotent stem cells have gained credence as a new reliable source of human tissues, 
with many advantages over the traditional in vitro cellular models.
2. Human pluripotent stem cells (IPSC)
Human pluripotent stem cells (hPSC) have the ability to expand to large amounts and dif-
ferentiate into any cellular tissue of the body [11]. Giving these extraordinary abilities, hPSC 
can potentially change the current paradigm in pharmacological research, offering unlimited 
access to a reliable source of neural tissue able to mimic early and late stages of human CNS 
development [2]. There are two types of hPSC: embryonic stem cells (hESC) and induced 
pluripotent stem cells (iPSC). Although both types share the same core features that classified 
them as hPSC, such as the ability of differentiating to any adult tissue, there are major differ-
ences between them. The hESC are derived from inner cell mass of blastocyst stage embryos 
after 5 days from the fertilization of the oocyte [12]. As of January 2017, 378 hESC lines were 
eligible for NIH fund research [13]. Comparatively, this library is still small to fully explore 
the whole human genomic diversity landscape. Moreover, giving its origin, hESC carry many 
ethical issues [14]. In spite of that, hESC have been pivotal on advancing the human stem cells 
research, permitting unlimited access to any human tissue of interest for the first time.
In 2006, a scientific breakthrough introduced a technique able to generate pluripotent stem 
cells without the ethical controversies of embryonic stem cells [15]. The team used the tech-
nique of reprogramming to reverse an adult mouse cell (fibroblast) into a pluripotent stem 
stage: the induced pluripotent stem cells (iPSC). Soon after the same research group pub-
lished the technique using human fibroblast to generate human-induced pluripotent stem 
cells (hiPSC) [16]. Once hiPSC have the same capacity as their hESC counterparts to generate 
human target cells in vitro, many scientists have shifted their focus into producing patient-
specific iPSC to potentially validate disease phenotypes in vitro [17]. For the nervous system, 
many studies confirmed the great potential of hiPSC in recapitulating CNS diseases [18, 19]. 
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Moreover, studies have revealed the potential of using hiPSC as a drug-screening platform 
to systematically evaluate spontaneous neurological disorders and drug-induced neurotox-
icity [17]. The biggest challenge for this approach is to identify key phenotypes in vitro for 
reproducible outcomes. Neurodevelopmental disorders, for example, impose such a signifi-
cant challenge. Recently, two studies that focused on different diseases (Rett Syndrome and 
MeCP2 Duplication Syndrome) successfully demonstrated the use of hiPSC-derived cells in 
identifying potential therapeutic candidates [20, 21]. Both neurodevelopmental disorders 
altered MeCP2 gene expression (loss of a functional copy in Rett Syndrome and overexpres-
sion in MeCP2 Duplication Syndrome). These studies identified core alterations in the syn-
apses of neurons in both conditions. In the MeCP2 Duplication Syndrome study, researchers 
developed a simplified drug-screening platform able to quickly assess the synaptic pheno-
type. By using a library of epigenetic modifiers, they identified two compounds that able to 
reverse the synaptic phenotype in vitro. However, the study also displays an alarming finding: 
although both potential therapeutic compounds identified in the study induced rescue of the 
cellular synaptic phenotype in vitro, one of them demonstrated significant toxicity on the CNS 
function in selected electrophysiology assays. This study highlights the need for an extensive 
characterization of drug toxicity in vitro before further consideration in human studies.
2.1. The current state-of-the-art of using hPSC for CNS safety screening
The extraordinary ability of hPSC to differentiate to CNS components makes them an interest-
ing platform to better understand the deleterious effects of compounds on neural tissue [11, 
22, 23]. Paired with cellular, genetic, biochemical, and functional assays, hPSC-derived neural 
tissue can be used to generate a comprehensive toxicological profile of drugs on the CNS 
and help to address decisions of go/no-go during a drug development process. Moreover, 
the brain undergoes significant postnatal development and its structure and function differ 
significantly between infantile and adult stages. Many drugs can affect the CNS differently, 
depending on the maturity of the subject (i.e., embryonic, infantile, or adult). Taken together, 
researchers may leverage hPSC-derived neural cells in different stages of differentiation to 
explore the safety profile of drugs on mature and immature nervous systems.
Neural precursor cells (NPCs) are multipotent cells, with the potential to generate multiple 
mature CNS cells, such as neurons, astrocytes, and oligodendrocytes [2, 24]. They are able to 
self-renew and proliferate, being pivotal players in the developing human brain. Toxicity to 
these cells at young stages of development can predispose the CNS to the onset of neurode-
velopmental disorders and neurological impairments [25]. NPCs can be expanded in vitro, 
which makes them amenable to incorporation into large-scale studies. Protocols to maintain 
and differentiate NPCs in their CNS derivatives are well established, with great consistency 
and reproducibility [2, 26]. Moreover, hiPSC from different individuals can be used to obtain a 
progenitor cell bank representative of genetic differences found on our population. Assessing 
toxicological profile in such a heterogeneous genomic population could improve predictabil-
ity of safety profiles of drugs on different individuals.
Publications with human NPCs started to demonstrate their use in assessing toxicological 
profile of drugs [25, 27]. Using hESC-derived NPCs, a research group described a platform 
for detection of toxicity to neuronal induction in embryonic development [28]. Researchers 
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exposed differentiating cells to methylmercury (MeHg) and found that it could disrupt early 
stages of neural differentiation. In another approach, researchers described the use of hESC-
derived NPCs in identifying compounds that were selectively toxic to progenitor, but innocu-
ous to terminally differentiated cells (neurons and astrocytes) [29]. Although the work was 
primarily envisioned as a platform to identify compounds able to deplete proliferation cells 
from heterogeneous neural populations in vitro, with applications in purifying populations 
for regenerative medicine, similar approach could also be used to elucidate the safety profile 
of chemical compounds on the CNS.
Differentiated populations of neurons have also been used to assess the toxicological profile 
of compounds [11]. Phenotypic assays such as neurite outgrowth and neuronal morphology 
have been used to investigate the effect of chemical entities on these populations. In a recent 
study, a library of 80 compounds was screened for their ability to inhibit neurite outgrowth 
in iPSC-derived neurons using a high-content screening platform [30]. From the compounds 
tested, 16 selectively inhibited neurite outgrowth, confirming the usefulness of hiPSC-derived 
neurons in neurotoxicity screenings. Although this study represents a step forward in devel-
oping a relevant humanized safety screening platform, it still relies on dissociated neurons 
plated at low density in vitro, which does not represent well the developed brain. Additionally, 
more sophisticated platforms, able to capture functional phenotypes, such as electrical activ-
ity of the neural circuitry, and the interplay between different CNS cell types will greatly help 
to improve the predictability of safety screenings.
2.2. Neural culture in vitro: from traditional tissue culture to organized organoids
Given the easy accessibility to CNS cells that hPSC offer, we have witnessed in the recent 
years the rediscovery of three-dimensional (3D) cell culture technologies as a powerful tool to 
study the brain [31, 32]. Organoids are 3D agglomerates of tissue-specific cells self-organized 
in structures that more closely resemble the target organ. Once organoids exhibit key struc-
tural and functional properties of a target tissue, they hold great promise in advancing the 
studies of complex organs such as the brain, where the interaction of many different cells 
organized in a defined structure is pivotal for its functions (Figure 2). Moreover, giving the 
complex interplay between neuronal and non-neuronal cells in the CNS, the deleterious effect 
of drugs may rely on non-neuronal cells (and not directly on neurons) but still lead to a pro-
nounced effect on the nervous system. In this scenario, brain organoids could better capture 
any deviation from the homeostatic balance of the interaction between different neural cells.
Two different types of cells can be used to obtain organoids: hPSC (using either ESC or iPSC) 
or multipotent adult stem cells [32]. Both approaches rely on the potential for expansion and 
self-organization of these precursors in vitro. Many recent studies have confirmed the used of 
brain organoids in the modeling of diseases by recapitulating in vitro the intricate and com-
plex processes occurring during human brain development. Moreover, brain organoid con-
structs incorporating many different cell types (such as neurons, astrocytes, endothelial, and 
microglia) can be obtained and used in developmental neurotoxicity screenings [33]. By using 
the described model, a recent study assessed the neurotoxicity profile of a library of 60 com-
pounds and correctly classified 9 of 10 chemicals. Although organoids containing different 
tissues would be a model more representative of the organ in vivo, the different tissue-specific 
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cells lack the  structural organization found in vivo and may not fully recapitulate the organ 
function or multi-tissue interactions.
3. Using MEA technology to evaluate neuroactivity of new chemicals
Cell viability, gene expression and neurite outgrowth assays with neurons have been the stan-
dard methods in vitro to measure deleterious effects of compounds on the CNS. In spite of their 
importance, they have limited predictability, especially with drugs able to evoke a deleterious 
functional change but without noticeable biochemical or cellular changes. Electrophysiology 
techniques exploit ionic conductance of ion channels and transient modulation of the mem-
brane potential of a neuron, being able to assess the functional status of the neural network 
in vitro [34]. There are many different techniques to record neuronal activity in vitro, with the most 
commonly used being the patch-clamp method. Although very sensitive, its low throughput 
and limitation of assessing only one or few neurons at a time precludes its use in investigating 
large neuronal circuitry dynamics [34]. Recently, new technologies of extracellular recordings 
have been developed. They have many advantages over traditional patch-clamp techniques, 
such as being noninvasive, capable of monitoring the culture for long periods of time, and 
Figure 2. In vitro models derived from hPSC. The main advantages and bottlenecks are listed. Brain organoids are 3D 
structures derived from hPSC differentiation toward neuroectoderm.
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able to record multiple cells at once, allowing large-scale assessment of neuronal circuitry 
dynamics [35]. This allows their use to better understand neuronal communication, informa-
tion encoding, propagation, processing, and computation of neuronal circuits in vitro [36].
One of the most promising technologies to record extracellular signaling is the microelectrode 
arrays (MEA). Uniquely, MEA platforms consist of hundreds to thousands of electrodes inte-
grated in a cell culture dish and enable recordings of neural activity by sensing extracellular 
field potentials [37]. This technology has been used to investigate the neural network dynam-
ics of hESC- and hiPSC-derived neuronal cultures, organotypic slice cultures and acute brain 
slices [34]. By combining multiple arrays, the MEA technology allows to investigate several 
conditions at the time in a high-throughput fashion. Moreover, because MEA is a noninvasive 
technology and the neurons are cultured directly onto the electrodes, this technology enables 
the repeated monitoring of intrinsic and inducible changes in neuronal network dynamics 
for several days which is extremely useful to investigate the relative effects of chronic drug 
exposure in a dish [35, 38].
Functional electrophysiology of neurons represents a powerful tool to investigate the safety 
pharmacology of drugs prior to first-in-human studies. It needs to be noted though that the 
human brain contains hundreds of different types of neurons, each with unique properties 
and pharmacological signal transduction pathways which may not be fully recapitulated 
in vitro. When mimicking the human brain in vitro, it is imperative to select the most appropriate 
cellular model to ensure unequivocally adequate and highly reproducible predictability [34]. 
Although mouse and rat primary neuronal cultures are the gold standard in MEA electro-
physiology, interspecies differences in ion-channel expression profile and neuronal response 
can be significantly different; therefore, translation of data to the human brain is very chal-
lenging in many situations [39]. The potential of using human PSC as a source of neuro-
nal circuitry mimicking the human brain just started to be explored [40]. While preliminary 
results are confirming the use of hiPSC-derived neural culture as a powerful tool to explore 
neurotoxicity of compounds on the human brain, more studies are warranted to address the 
variability and heterogeneity of such cell culture models.
4. Overcoming current bottlenecks of hiPSC-derived cultures
Giving the high degree of complexity of the CNS cellular components, full translation from 
in vitro studies of compound-induced neurotoxicity can be challenging [40]. In the recent years, 
the stem cell field has produced diverse protocols for obtaining hiPSC-derived neurons in vitro, 
making any attempt to standardize the field complicate once each laboratory uses its own pro-
tocol. Moreover, the field is also subjected to batch-to-batch variation and long period of time 
differentiation protocols, which introduce additional challenges in reproducibility and hampers 
its full adoption by screening companies. Recently, however, a number of hiPSC-derived neu-
rons became commercially available. Homogenous populations of neurons with specific neu-
rotransmitter profiles are an attractive alternative to study the human physiology. The reduced 
variability from batch-to-batch and controlled differentiation process make possible the repro-
ducible use of these cells to investigate neurotoxicity on the CNS. One thing to be noted though 
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is the difference between hiPSC-derived products offered by different companies. Additionally, 
while most companies focus on highly pure populations of neurons, depleted of glia cells, this 
model may not be ideal to mimic the CNS complexity. The presence of astrocytes, for example, 
are important to modulate the response of neurons to neurotransmitters and can affect the 
vulnerability of neuronal cultures to toxic insults [41, 42]. Moreover, co-culture with astrocytes 
enhances synaptic maturation, with consequences on firing frequency and bursting behavior 
[43, 44]. Although still an emerging field with many questions to be answered, commercially 
available hiPSC-derived neurons and astrocytes will be pivotal in validating this model as a 
suitable solution to reduce (or even replace) animal experimentation in toxicology studies.
5. Conventional drug development process and Zika virus
In February of 2016 the World Health Organization (WHO) declared the Zika virus infec-
tion a Public Health Emergency of International Concern (PHEIC), which prompted scientist 
worldwide to an urgent and coordinated response to this new global threat. Zika virus was 
first identified in 1947, but only recently received public attention after being associated with 
microcephaly in newborns and Guillain-Barré syndrome in adults [45, 46]. Two recent studies 
screened libraries of FDA-approved drugs and identified potential therapeutics with novel 
activity against the Zika virus [47, 48]. Repurposing FDA-approved drugs can potentially 
accelerate the discovery of cures to diseases, reducing time, and costs. However, both stud-
ies lack extensive neurotoxicity characterization of the potential therapeutics. Although the 
library consisted of FDA-approved compounds, the active concentrations against the virus 
were relatively high and not necessarily safe to human use. Moreover, it is pivotal to assess 
the safety of these compounds in early stages of the CNS development before considering 
them to treat pregnant women or newborns. In a recent scientific communication, our group 
demonstrated that many of the compounds identified on the mentioned studies were in fact 
toxic at their effective concentrations against Zika virus [49]. We investigated the toxicological 
profile of 29 compounds described as potential therapeutic against Zika virus infection. By 
testing hiPSC-derived cells at different stages of the CNS development, we observed greater 
toxicity at early stages of the nervous system, with decreasing toxicity as the cells matured 
in vitro. Interestingly, Emricasan (a compound highlighted in a previous publication) dem-
onstrated a safe toxicological profile in all stages of the CNS and did not interfere with the 
normal function of mature neural cultures, as assessed by calcium mobilization assays using 
a fluorescent imaging plate reader (FLIPR) platform and electrophysiology using MEA [48]. 
Nonetheless, this study emphasized the need for extensive early characterization of repur-
posed compounds before considering them to potentially alleviate new diseases.
6. Conclusion/remarks
There is an urgency to accelerate and streamline the process of the development of new 
drugs. From devastating neurodegenerative disorders, such as Alzheimer’s, to global threats, 
Neurotoxins8
epidemics from known and unknown viruses, we need to be able to rapidly identify safe 
therapeutic compounds. The average time to translate a drug from the bench to the clinic is 10 
years, with an approximate cost of $2.6 billion dollars. One contributor for this is the fact that 
the current drug development process is very inefficient, with fewer than 10% of the drugs 
in development being approved for use [50]. Adverse drug reactions to CNS are responsible 
for a large amount of all drug attrition cases [51]. To change the current scenario, it is cru-
cial to have available a toolbox able to quickly assess the toxicological profile in early steps 
of drug development. The incredible potential of hPSC to expand in vitro and differentiate 
toward any adult cell type makes them ideal tools to large-scale toxicology studies. Together 
with techniques able to assess functional phenotype in real time, such as MEA technology, 
terminally differentiated neurons derived from hPSC could help to improve clinical outcome 
predictability in early steps of the clinical trial, reducing overall costs and turnover of the 
drug development process.
In an attempt to streamline the discovery, development, and delivery of new cures, the House 
of Representatives of the United States of America recently passed the 21st Century Cures 
Act [52]. The bill will allocate funds to the National Institute of Health (NIH) and help to fast 
track the approval of new drugs by the Food and Drug Administration (FDA). The Cures 
Act will also provide funding for three innovative scientific initiatives: the Brain Research 
through Advancing Innovative Neurotechnologies (BRAIN) Initiative, the Precision Medicine 
Initiative (PMI) and the Beau Biden Cancer Moonshot Initiative [53]. Moreover, the Cures Act 
also simplifies the process of data sharing, allowing the quick use of data by the scientific 
community. The BRAIN initiative aims to elucidate how the neural network works in health 
brains and what is altered in neurological disorders. The building of knowledge on these 
brain states is pivotal to any drug development workflow. However, although initiatives as 
the BRAIN are required to advance our medical knowledge about the CNS, it is crucial to 
develop new platforms able to recapitulate these findings in vitro. To this end, platforms to 
assess adverse drug effects on the CNS using hiPSC are pointed as the most promising and 
currently being developed [17].
Human iPSC already started to revolutionize disease modeling in vitro, revealing disease 
mechanisms otherwise not seen using classical animal models. Moreover, once hiPSC can be 
derived from any individual, it enables their use in personalized medicine, including toxi-
cological screening in individual-specific tissues to reveal the potential side effects of drugs 
before their use. One caveat though is the simplified representation of the nervous system 
tissue architecture that can be obtained in vitro using hiPSC-derived cell culture techniques. 
In an attempt to overcome this limitation, the field is seen as a re-emergence of 3D organoids. 
Recent studies with brain organoids have confirmed their potential in recapitulating steps of 
the human brain development and organization. The development of new 3D high-content 
screening technologies, such as Light Sheet Microscopy, and improved differentiation proto-
cols will be critical to a broad adoption of this technology in drug development screenings. 
Moreover, they can be an attractive alternative in replacing animal use in certain applications 
as well in guiding conventional clinical trial studies for dose tolerance in humans. In prin-
ciple, the use of brain organoids in screenings could help to provide a more fine-tuned and 
multipronged approach to understand the risks and benefits of new therapies [10].
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In addition to hPSC, the repurposing of old drugs to new diseases have gained attention in the 
recent years and promise to revolutionize the drug discovery field [54]. Repurposing drugs 
could significantly decrease the time and costs to find new therapies. However, it is still cru-
cial to re-evaluate their toxicological profile. When redirecting compounds to new diseases, 
their new efficacy dosage need to be extensively tested to assure safety on the clinic, once 
many redirected compounds present a higher effective concentration for 50% of the maxi-
mum response (IC
50
) and may not be clinically relevant. The recent example of repurposing 
drugs to Zika virus found many hits with a higher IC
50
 than the safest dosage identified in 
a toxicological screening using hiPSC-derived neural progenitor cells, preventing their use 
in newborns and pregnant women [48, 49]. Drug combination therapy, using two or three 
compounds found in the repurposing screening, could potentially increase the success rate of 
such screening by synergistic effects of the combination [54]. Successfully synergistic combi-
nations of drugs would enable the reduction of each drug dosage to nontoxic levels and allow 
to use a therapeutic concentration that is below or equal to their achievable human blood 
concentrations.
Finally, the Zika virus prompted the scientific community to react and collaborate in a 
fashion not seen before. Different fields joined forces sharing a common goal: discover 
new therapies and vaccines to an emerging global threat. It also highlighted the need to 
change the current drug development workflow. In face of such threats, new tools are 
needed allowing researchers to quickly identify new therapeutic compounds. Elements 
discussed on this chapter, such as hPSCs and their derivatives, combined with MEA elec-
trophysiology will streamline this process and be the standard toxicological assays in the 
future.
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